Baudax Bio Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Baudax Bio (BXRX) Misses Q2 EPS by $1.07
August 10, 2020 7:18 AM EDTBaudax Bio (NASDAQ: BXRX) reported Q2 EPS of ($1.72), $1.07 worse than the analyst estimate of ($0.65).
The second quarter of 2020 was most important because of the full commercial launch of ANJESO, said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. We believe that with... More
